SAN DIEGO, February 24, 2020 – Imbria Pharmaceuticals, Inc. today announced that Imbria Pharmaceuticals will present at the SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 2:00 pm ET at the Lotte New York Palace Hotel, New York, NY. David-Alexandre C. Gros, M.D., President and Chief Executive Officer, and Heidi Henson, Chief Financial Officer, will present at the conference.
About Imbria Pharmaceuticals
Imbria Pharmaceuticals uses our deep understanding of cellular energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. Our lead program, IMB-101, is currently initiating enrollment in a Phase 2b clinical trial for refractory angina. Our additional product candidates, IMB-202 and IMB-203, are designed to address cellular energy deficiency in patients with rare genetic mutations in mitochondrial metabolism, including those with inborn errors of metabolism. For additional information, please visit www.imbria.com.